PROPOFOL-II INJECTION EMULSION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
02-10-2018
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
PROPOFOL
Tillgänglig från:
PFIZER CANADA ULC
ATC-kod:
N01AX10
INN (International namn):
PROPOFOL
Dos:
10MG
Läkemedelsform:
EMULSION
Sammansättning:
PROPOFOL 10MG
Administreringssätt:
INTRAVENOUS
Enheter i paketet:
20ML
Receptbelagda typ:
Prescription
Terapiområde:
MISCELLANEOUS GENERAL ANESTHETICS
Produktsammanfattning:
Active ingredient group (AIG) number: 0121833001; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2020-02-24
Produktens egenskaper
_Product Monograph – _
_Pr_
_Propofol-II Injection _
_ _
_Page 1 of 54_
_ _
PRODUCT MONOGRAPH
PR
PROPOFOL-II INJECTION 1% w/v
propofol injection
10 mg/mL
Pfizer Standard
Intravenous Emulsion – Anaesthetic - Sedative
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Revision:
October 2, 2018
Submission Control No.: 219498
_Product Monograph – _
_Pr_
_Propofol-II Injection _
_ _
_Page 2 of 54_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
5
ADVERSE REACTIONS
...............................................................................................
10
DRUG INTERACTIONS
...............................................................................................
15
DOSAGE AND ADMINISTRATION
...........................................................................
15
OVERDOSAGE
..............................................................................................................
24
ACTIONS AND CLINICAL
PHARMACOLOGY........................................................
24
STORAGE AND STABILITY
.......................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 28
PART II: SCIENTIFIC INFORMATION
.............................................................................
29
PHARMACEUTICAL INFORMATION
.......................................................................
29
DETAILED PHARMACOLOGY
.....................................................................
Läs hela dokumentet
